Skip to content

VALOPHAR

Active Private limited companyfounded 2012active for 13 yearsRue de la Croix-Rouge, Bos. 20, 5032 GemblouxKBO/BCE: BE 0508.535.267

Lifetime

13 annual accounts with figures on one time axis
peak of €226,822 in 2024
€204,905▼ 9.7%
lowest -€25,754 in 2019
€30,875▼ 43.8%
peak of €262,898 in 2025
€262,898▲ 12.5%
€756,180▼ 5.5%
peak of 1.4 FTE in 2025
1.4 FTE▲ 55.6%
Board2 names since 2012
2 directors and 1 other
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Result from €54,973 to €30,875Staff from 0.9 FTE to 1.4 FTEDividend €1,600Equity from €233,623 to €262,898

Key points

from the 2025 annual accounts

Equity

€262,898 ▲ 12.5%

VALOPHAR has made a profit without a break since 2020.

Debts

€756,180 74% of the balance sheet
Financial debts 68%Suppliers 21%Taxes and wages 4%Other 8%

Of this, €241,725 falls due within a year.

Filings

13 annual accounts since 2013
AprilJune31 JulyOctober201520202025

Ten of the last ten came late. The 2023 accounts came in latest, 61 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 4,515 companies had the same profile as VALOPHAR has now. Each dot stands for 12 companies, two years later.

96.8%
were still trading
1.7%
stopped another way
1.4%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 4,515 companies, not a prediction for VALOPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
  • 150 sharesdeed of 20-12-2012
  • 150 sharesdeed of 20-12-2012
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0508535267
(director) and (director) change roles Gazette deed
New establishment in Gembloux Pharmacie Brodéoux, Chaussée de Namur 390
First establishment Valophar sprl, Rue de la Croix-Rouge, Bos. 20, Gembloux
All 25 events

Comparable companies

same main activity, similar in size and age
Company
VALOPHAR Gembloux €1.0m €204,905 25.8% 1.4
PIRET INVEST Namur €1.0m €238,163 87.2% 1.5
Pharmaphie SDW Ghent €1.2m €193,543 35.5% 1.3
SMETS FARMA Antwerp €0.9m €231,488 31.5% 1.5
Lo Farma Lochristi €0.9m €187,394 32.7% 1.6
Apotheek C. Wouters Lommel €1.1m €237,965 81.4% 1.2
MANAGEMENT JUMAPA Hoegaarden €1.0m €225,195 44.2% 1

These companies have the same main activity as VALOPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €875,000 and €1.2m, founded between 2010 and 2013.

Official details

Source: KBO
Status
Active since 18-12-2012Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment units
2.214.997.4735032 Gembloux, since 01-01-2013
2.311.909.9755030 Gembloux, since 14-07-2019
Financial year end
31 December
Peppol
Reachable since 24-11-2025
Company details

Annual accounts 2025

≈ €960,000estimated
€1.0m▼ 1.4%
Employeeson 31-12-2025
3
Filing
Filed on 31-08-2026
Financials

Insights on VALOPHAR

VALOPHAR files the abbreviated format. That format states no turnover. The gross margin rose from €75,430 in 2013 to €204,905 in 2025.

The balance sheet grew most from 2017 to 2019 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about VALOPHAR

What is the company number of VALOPHAR?
The company number of VALOPHAR is 0508.535.267. The VAT number is the same number with BE in front: BE 0508.535.267.
Where is VALOPHAR based?
The registered office is at Rue de la Croix-Rouge, Bos. 20, 5032 Gembloux.Company details
What does VALOPHAR do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of VALOPHAR?
VALOPHAR is a private limited company (BV).
When was VALOPHAR founded?
VALOPHAR was founded on 18-12-2012.
Is VALOPHAR still active?
Yes, VALOPHAR is an active enterprise in the KBO register.
How many employees does VALOPHAR have?
VALOPHAR had an average of 1.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does VALOPHAR fall under?
In its 2025 annual accounts, VALOPHAR states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of VALOPHAR?
The turnover in financial year 2025 is about €960,000. This figure is estimated from the gross margin of €204,905 and 43 comparable companies (NACE 477). It probably lies between €630,000 and €2.0m.
Is VALOPHAR profitable?
In financial year 2025, VALOPHAR made a profit of €30,875.
Where can I find the annual accounts of VALOPHAR?
VALOPHAR filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of VALOPHAR due?
VALOPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.